Codexis

From Wikipedia, the free encyclopedia

Template:Short description Template:Undisclosed paid

Page Module:Infobox/styles.css has no content.Page Template:Infobox company/styles.css has no content.

Codexis, Inc.
Company type
Public
Nasdaq: CDXS
Russell 2000 Component
ISINScript error: No such module "WikidataIB".
IndustryScript error: No such module "WikidataIB".
PredecessorScript error: No such module "WikidataIB".
IncorporatedScript error: No such module "WikidataIB".
FoundedScript error: No such module "WikidataIB".
FounderScript error: No such module "WikidataIB".
DefunctScript error: No such module "WikidataIB".
SuccessorScript error: No such module "WikidataIB".
HeadquartersRedwood City, California, U.S.
Key people
Page Template:Plainlist/styles.css has no content.
RevenueScript error: No such module "WikidataIB".
Script error: No such module "WikidataIB".
Script error: No such module "WikidataIB".
Total assetsScript error: No such module "WikidataIB".
Number of employees
Script error: No such module "WikidataIB".
ParentScript error: No such module "WikidataIB".
Websitecodexis.com

Script error: No such module "Check for conflicting parameters".Script error: No such module "Check for deprecated parameters".

Codexis, Inc. is a protein engineering company that develops enzymes for pharmaceutical, food and medical applications.[2][3]

History

Codexis is based in Redwood City, CA and was incorporated in 2002. It went public in April 2010 on NASDAQ,[4] and in October, acquired Maxygen's MolecularBreeding technology portfolio.[5]

Pharmaceutical

Codexis won the Presidential Green Chemistry Challenge Award from the U.S. Environmental Protection Agency (EPA) in 2006 for its work on a building block of Lipitor.[6] It then won a second time in 2010 for its work with Merck & Co. on the active ingredient in Januvia.[7]

Nutrition

In 2017, the company entered a partnership with Tate & Lyle to provide research and development for the production of new ingredients.[8] That same year, Codexis announced a collaboration with Nestle to provide enzymes for metabolic disorders.[9]

Biotherapeutics

In 2017, Codexis developed a recombinant phenylalanine ammonia-lyase (PAL) enzyme, to act as a substitute phenylalanine hydroxylase (PAH) enzyme for people who suffer from phenylketonuria.[3] The enzyme was in-licensed by Nestle Health Sciences.[3]

In 2020, Takeda Pharmaceutical announced a collaboration with Codexis to research and create gene therapies for rare diseases, including lysosomal storage disorders.[10]

Life science

In June 2020, they announced a partnership with Molecular Assemblies to engineer enzymes for DNA synthesis.[11]

Technology

Codexis uses directed evolution to develop its enzymes.[12][13] Using this method, scientists genetically engineer genes, then screen the enzymes produced to see if it creates the properties needed for a specific reaction.[13][7] Their protein engineering platform, called CodeEvolver, uses machine learning and high-throughput experimentation to learn protein sequence changes and their impacts on protein function.[3][14]

References

Page Template:Reflist/styles.css has no content.

  1. ^ Page Module:Citation/CS1/styles.css has no content."Codexis Overview". Retrieved 2011-04-03.
  2. ^ Page Module:Citation/CS1/styles.css has no content."Codexis, Molecular Assemblies Ink Enzyme Engineering Collaboration Agreement". GenomeWeb. 23 June 2020. Retrieved 2021-03-12.
  3. ^ a b c d Page Module:Citation/CS1/styles.css has no content.Hyde, Embriette (2019-09-04). "Engineering the future of biotherapeutics". SynBioBeta. Retrieved 2021-03-12.
  4. ^ Page Module:Citation/CS1/styles.css has no content.Gelsi, Steve. "Codexis IPO blossoms on Earth Day". MarketWatch. Retrieved 10 June 2021.
  5. ^ Page Module:Citation/CS1/styles.css has no content."License Agreement - Maxygen, Inc". www.sec.gov.
  6. ^ Page Module:Citation/CS1/styles.css has no content."Codexis, Inc.:News Release".{{cite web}}: CS1 maint: deprecated archival service (link)
  7. ^ a b Page Module:Citation/CS1/styles.css has no content."Greener approach to Januvia cuts costs, ups yield". Reuters. 17 June 2010 – via www.reuters.com.
  8. ^ Page Module:Citation/CS1/styles.css has no content.foodnavigator.com. "Tate & Lyle announce multiyear partnership with Codexis". foodnavigator.com. Retrieved 2021-05-27.
  9. ^ Page Module:Citation/CS1/styles.css has no content.Mullin, Rick (2017-11-13). "BASF readies a medical food product". Chemical & Engineering News. Archived from the original on 2019-08-04. Retrieved 2021-05-27.
  10. ^ Page Module:Citation/CS1/styles.css has no content."Codexis and Takeda partner on gene therapies for rare diseases". www.pharmaceutical-technology.com. Retrieved 2021-06-18.
  11. ^ Page Module:Citation/CS1/styles.css has no content."Codexis, Molecular Assemblies Ink Enzyme Engineering Collaboration Agreement". Genomeweb. 2020-06-23. Retrieved 24 June 2021.
  12. ^ Page Module:Citation/CS1/styles.css has no content.says, Jerry Jeff (2010-10-27). "Xconomy: Codexis Morphs From Big Science Project Into $100M Business". Xconomy. Retrieved 2021-05-24.
  13. ^ a b Page Module:Citation/CS1/styles.css has no content.says, Jerry Jeff (2010-10-27). "Xconomy: Codexis Morphs From Big Science Project Into $100M Business". Xconomy. Retrieved 2021-06-02.
  14. ^ Page Module:Citation/CS1/styles.css has no content."Patenting Considerations for Artificial Intelligence in Biotech and Synthetic Biology". JD Supra.
  • No URL found. Please specify a URL here or add one to Wikidata.

Lua error in package.lua at line 80: module 'Module:Authority control/config' not found.

Retrieved from "https://cosmopedia.co/index.php?title=Codexis&oldid=4560748"